NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
2.31
Dollar change
+0.04
Percentage change
1.76
%
Index- P/E- EPS (ttm)-6.36 Insider Own1.53% Shs Outstand2.37M Perf Week4.05%
Market Cap5.48M Forward P/E- EPS next Y-0.05 Insider Trans0.00% Shs Float2.33M Perf Month0.43%
Enterprise Value2.34M PEG- EPS next Q-1.01 Inst Own14.90% Short Float12.58% Perf Quarter-12.50%
Income-6.82M P/S0.88 EPS this Y65.59% Inst Trans115.98% Short Ratio0.17 Perf Half Y-73.20%
Sales6.22M P/B1.25 EPS next Y98.73% ROA-140.74% Short Interest0.29M Perf YTD-71.62%
Book/sh1.85 P/C1.80 EPS next 5Y- ROE-200.53% 52W High14.67 -84.25% Perf Year-69.19%
Cash/sh1.29 P/FCF- EPS past 3/5Y87.10% - ROIC-223.55% 52W Low1.62 42.59% Perf 3Y-99.87%
Dividend Est.- EV/EBITDA- Sales past 3/5Y13.84% - Gross Margin- Volatility5.17% 7.00% Perf 5Y-99.99%
Dividend TTM- EV/Sales0.38 EPS Y/Y TTM87.94% Oper. Margin-110.13% ATR (14)0.16 Perf 10Y-
Dividend Ex-Date- Quick Ratio2.50 Sales Y/Y TTM256.35% Profit Margin-109.51% RSI (14)53.79 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio2.50 EPS Q/Q83.09% SMA205.58% Beta1.01 Target Price18.45
Payout- Debt/Eq0.08 Sales Q/Q331.69% SMA50-2.19% Rel Volume0.01 Prev Close2.27
Employees9 LT Debt/Eq0.00 EarningsMay 13 AMC SMA200-53.23% Avg Volume1.77M Price2.31
IPOFeb 26, 2018 Option/ShortNo / Yes EPS/Sales Surpr.53.90% - Trades Volume9,667 Change1.76%
Jun-24-25 08:00AM
Jun-11-25 08:00AM
Jun-04-25 08:00AM
May-13-25 04:15PM
May-12-25 08:00AM
04:15PM Loading…
Apr-24-25 04:15PM
Apr-23-25 04:41PM
08:00AM
Apr-15-25 08:00AM
Mar-31-25 08:00AM
Mar-18-25 08:00AM
Mar-13-25 08:00AM
Mar-10-25 04:15PM
Mar-05-25 08:00AM
Mar-03-25 09:43AM
08:00AM Loading…
Feb-05-25 08:00AM
Jan-22-25 08:00AM
Jan-08-25 08:00AM
Dec-23-24 08:00AM
Dec-10-24 08:00AM
Dec-04-24 08:00AM
Dec-03-24 04:15PM
Nov-26-24 08:00AM
Nov-12-24 04:15PM
Nov-07-24 08:00AM
Oct-08-24 08:00AM
Oct-02-24 08:00AM
Sep-27-24 04:30PM
Sep-24-24 08:00AM
Sep-19-24 07:00AM
08:00AM Loading…
Sep-13-24 08:00AM
Aug-29-24 08:00AM
08:00AM
Aug-27-24 02:30PM
08:00AM
Aug-23-24 08:00AM
Aug-14-24 04:15PM
Aug-08-24 08:25AM
Jul-23-24 08:00AM
Jul-09-24 08:00AM
Jun-27-24 08:00AM
Jun-25-24 08:00AM
Jun-24-24 10:52AM
Jun-06-24 08:00AM
Jun-03-24 08:00AM
May-28-24 08:00AM
May-20-24 08:00AM
May-13-24 08:00AM
Apr-25-24 08:00AM
Apr-19-24 08:00AM
Apr-09-24 08:00AM
Mar-18-24 10:53AM
Mar-15-24 08:00AM
Feb-27-24 08:00AM
Feb-21-24 08:00AM
Feb-15-24 08:00AM
Feb-13-24 08:00AM
Feb-06-24 08:00AM
Jan-31-24 08:00AM
Jan-25-24 08:00AM
Jan-23-24 08:00AM
Jan-08-24 08:15AM
Dec-19-23 04:15PM
Dec-14-23 08:15AM
Dec-11-23 09:00AM
Nov-29-23 08:05AM
Nov-28-23 08:15AM
Nov-16-23 08:15AM
Nov-09-23 04:30PM
Oct-24-23 08:15AM
Oct-18-23 08:15AM
Oct-13-23 08:15AM
Oct-11-23 08:15AM
Oct-03-23 08:15AM
Sep-26-23 08:15AM
Sep-19-23 08:15AM
Sep-14-23 08:15AM
Sep-07-23 08:15AM
Sep-05-23 08:15AM
Aug-14-23 08:15AM
Aug-11-23 08:00AM
Aug-08-23 08:15AM
07:05AM
Jul-26-23 08:05AM
Jun-27-23 08:05AM
Jun-15-23 01:34PM
Jun-13-23 04:15PM
Jun-07-23 09:55AM
Jun-06-23 08:05AM
May-16-23 07:25AM
May-15-23 04:30PM
May-12-23 04:40PM
May-10-23 08:00AM
May-09-23 01:31PM
08:00AM
07:45AM
Apr-21-23 03:59PM
Apr-19-23 09:25AM
Apr-11-23 08:10AM
Apr-03-23 08:06AM
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.